Literature DB >> 8111309

Regulation of megakaryocytopoiesis.

H Avraham1.   

Abstract

Megakaryocytopoiesis is the cellular developmental process prior to the release of platelets into the circulation. Regulation of megakaryocytopoiesis is a complex phenomenon that begins with commitment of hematopoietic stem cells to the replication and maturation of progenitor cells through endomitosis and megakaryocyte differentiation [1-4]. Platelet production is determined by the number and size of megakaryocytes in the marrow and may be regulated at two levels: at early stages of cell proliferation resulting in increased megakaryocyte numbers, and at later stages by endoreplication which increases DNA content and the size of megakaryocytes [5]. The mature megakaryocyte is a large polyploid cell with a highly defined invaginated membrane (demarcation membrane) and contains the membrane molecules necessary for platelet function [6-9]. Platelet shedding appears to occur by fragmentation of the cytoplasm of the megakaryocyte. Platelet release is thought to occur via transendothelial processes projecting into the vascular compartment [10, 11], although several studies indicate that megakaryocytes lodged in the lungs are capable of platelet formation [12-17]. The factors stimulating megakaryocytopoiesis in the lung have not been well characterized. In the past, the study of megakaryocyte development in vivo and in vitro was hampered by the rarity of megakaryocytes in the bone marrow, the poorly defined cell populations, and inadequate assays. These prior studies of megakaryocyte development have been discussed in the recent past by R. Hoffman [1], N. Williams [3], and M. W. Long [2]. An attempt will be made in this review to highlight and synthesize various new concepts of regulation of megakaryocytopoiesis.

Mesh:

Substances:

Year:  1993        PMID: 8111309     DOI: 10.1002/stem.5530110619

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

1.  RGS18 is a myeloerythroid lineage-specific regulator of G-protein-signalling molecule highly expressed in megakaryocytes.

Authors:  D Yowe; N Weich; M Prabhudas; L Poisson; P Errada; R Kapeller; K Yu; L Faron; M Shen; J Cleary; T M Wilkie; C Gutierrez-Ramos; M R Hodge
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

2.  Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.

Authors:  Rachelle E Kosoff; Joseph E Aslan; John C Kostyak; Essel Dulaimi; Hoi Yee Chow; Tatiana Y Prudnikova; Maria Radu; Satya P Kunapuli; Owen J T McCarty; Jonathan Chernoff
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

3.  Stem cell factor (SCF) synergizes with megakaryocyte colony stimulating activity in post-irradiated aplastic plasma in stimulating human megakaryocytopoiesis.

Authors:  V R Deutsch; A Eldor; T Olson; V Barak; M Pick; A Nagler
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

Review 4.  Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family?

Authors:  Harold J Ting; Fadi T Khasawneh
Journal:  J Biomed Sci       Date:  2010-04-06       Impact factor: 8.410

5.  In vivo inactivation of MASTL kinase results in thrombocytopenia.

Authors:  H Jan Johnson; Manish J Gandhi; Ebrahim Shafizadeh; Nathaniel B Langer; Eric L Pierce; Barry H Paw; Diana M Gilligan; Jonathan G Drachman
Journal:  Exp Hematol       Date:  2009-05-19       Impact factor: 3.084

6.  In Vitro and Ex Vivo Approaches to Evaluate Next-Generation Tobacco and Non-Tobacco Products on Human Blood Platelets.

Authors:  Sherry L Spinelli; Katie L Lannan; Shannon G Loelius; Richard P Phipps
Journal:  Appl In Vitro Toxicol       Date:  2017-03-01

7.  Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation.

Authors:  T Hamada; R Möhle; J Hesselgesser; J Hoxie; R L Nachman; M A Moore; S Rafii
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.